emcdonald on DSK5VPTVN1PROD with NOTICES

64948 Federal Register / Vol. 76, No. 202 / Wednesday, October 19, 2011 / Notices 

Marija Manojlovic, University of 

Pittsburgh: Based on an inquiry 

conducted and written admission 

obtained by the University of Pittsburgh 

(UP) and additional analysis conducted 

by ORI in its oversight review, ORI 

found that Ms. Marija Manojlovic, 

former graduate student, Department of 

Chemistry, UP, engaged in research 

misconduct in research supported by 

National Institute of General Medical 

Sciences (NIGMS), National Institutes of 

Health (NIH), grant P50 GM067082, 

National Cancer Institute (NCI), NIH, 

grant P01 CA078039, National Institute 

of Mental Health (NIMH), NIH, grant 

U54 MH074411, and National Institute 

of Allergy and Infectious Diseases 

(NIAID), NIH, grant R01 AI033506. 

ORI found that the Respondent 

engaged in research misconduct by 

falsifying and fabricating the synthesis 

and spectral data that were included in 

one (1) poster presentation and in one 

(1) pre-submission draft of a paper to be 

submitted for publication. 

Specifically, ORI found that the 

Respondent knowingly falsified and 

fabricated the synthesis and 

characterization, largely in the form of 

manipulated 1H- and 13C–NMR spectral 

data, for five intermediate steps and the 

final product, 9-desmethylpleurotin, 

and presented these false results in a 

poster, ‘‘Efforts Towards the Total 

Synthesis of Pleurotin,’’ presented at the 

2011 National Organic Symposium, and 

in a manuscript, ‘‘Total Synthesis of 9-

desmethylpleurotin,’’ prepared for 

submission to Angewandte Chemie 

International Edition. 

Ms. Manojlovic has voluntarily agreed 

for a period of three (3) years, beginning 

on September 26, 2011: 

(1) To have her U.S. Public Health 

Service (PHS)-supported research 

supervised; Respondent agreed that 

prior to the submission of an 

application for PHS support for a 

research project on which her 

participation is proposed and prior to 

her participation in any capacity on 

PHS-supported research, she shall 

ensure that a plan for supervision of her 

duties is submitted to ORI for approval; 

the supervision plan must be designed 

to ensure the scientific integrity of her 

research contribution; Respondent 

agreed that she shall not participate in 

any PHS-supported research until such 

a supervision plan is submitted to and 

approved by ORI; Respondent agreed to 

maintain responsibility for compliance 

with the agreed upon supervision plan; 

(2) That any institution employing her 

shall submit, in conjunction with each 

application for PHS funds, or report, 

manuscript, or abstract involving PHSsupported research in which she is 

involved, a certification to ORI that the 

data provided by Respondent are based 

on actual experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are 

accurately reported in the application, 

report, manuscript, or abstract; and 

(3) To exclude herself from serving in 

any advisory capacity to PHS including, 

but not limited to, service on any PHS 

advisory committee, board, and/or peer 

review committee, or as a consultant. 

FOR FURTHER INFORMATION CONTACT: 

Director, Division of Investigative 

Oversight, Office of Research Integrity, 

1101 Wootton Parkway, Suite 750, 

Rockville, MD 20852, (240) 453–8800. 

John Dahlberg, 

Director, Division of Investigative Oversight, 

Office of Research Integrity. 

[FR Doc. 2011–27022 Filed 10–18–11; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Decision To Evaluate a Petition To 

Designate a Class of Employees From 

Oak Ridge National Laboratory (X–10), 

Oak Ridge, TN, To Be Included in the 

Special Exposure Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Department of Health and 

Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice as required 

by 42 CFR 83.12(e) of a decision to 

evaluate a petition to designate a class 

of employees from Oak Ridge National 

Laboratory (X–10), Oak Ridge, 

Tennessee, to be included in the Special 

Exposure Cohort under the Energy 

Employees Occupational Illness 

Compensation Program Act of 2000. The 

initial proposed definition for the class 

being evaluated, subject to revision as 

warranted by the evaluation, is as 

follows: 

Facility: Oak Ridge National 

Laboratory (X–10) 

Location: Oak Ridge, Tennessee. 

Job Titles and/or Job Duties: All 

contractor employees, subcontractor 

employees, and AEC employees who 

were monitored or should have been 

monitored for any of the various 

radionuclides and fission products 

present at the X–10 plant. 

Period of Employment: January 1, 

1943 through December 31, 1952. 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 877– 

222–7570. Information requests can also 

be submitted by e-mail to 

DCAS@CDC.GOV. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2011–27035 Filed 10–18–11; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Senior Executive Service 

Performance Review Board 

Membership 

The Agency for Healthcare Research 

and Quality (AHRQ) announces the 

appointment of members to the AHRQ 

Senior Executive Service (SES) 

Performance Review Board (PRB). This 

action is being taken in accordance with 

5 U.S.C. 4314(c)(4), which requires 

notice of appointment of members to 

performance review boards to be 

published in the Federal Register. 

Members of the PRB are appointed in 

a manner that will ensure consistency, 

stability and objectivity in the SES 

performance appraisals. The function of 

the PRB is to make recommendations to 

the Director, AHRQ, relating to the 

performance of senior executives in the 

Agency. 

The following persons will serve on 

the AHRQ SES Performance Review 

Board: 

Irene Fraser, Stephen B. Cohen, William 

Munier, David Meyers, Michael 

Fitzmaurice, Phyllis Zucker, Mark 

Handelman, Jean Slutsky. 

For further information about the 

AHRQ Performance Review Board, 

contact Ms. Alison Reinheimer, Office 

of Performance, Accountability, 

Resources, and Technology, Agency for 

Healthcare Research and Quality, 540 

Gaither Road, Suite 4012, Rockville, 

Maryland 20850. 

Dated: October 2, 2011. 

Carolyn M. Clancy, 

Director, AHRQ. 

[FR Doc. 2011–26965 Filed 10–18–11; 8:45 am] 

BILLING CODE 4160–90–M